13.01.2025Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2024 accomplishments and upcoming milestones.
09.01.2025Er kennt VEGA bis ins kleinste Detail und hat den Hersteller für Füllstand- und Druckmesstechnik aus Schiltach geprägt wie kaum ein anderer: Nach mehr als 50 Jahren im Unternehmen, davon 25 Jahre in der Geschäftsleitung, geht Günter Kech zum 31. Dezember 2024 in den Ruhestand. Rückblick auf eine bemerkenswerte Karriere.
10.01.2025The leading provider of processing and packaging solutions Syntegon has completed the construction of its new office building at its Crailsheim premises. Site manager Albrecht Werner officially opened the new facility on December 12 before employees moved in to take up their new workplaces. Syntegon completed the project ahead of schedule after just over a year and a half in the works. The building was originally slated to open in the first half of 2025.
16.01.2025Siegfried has been once again recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability Index Europe (DJSI) for the fourth consecutive year.
13.01.2025Siegfried has been once again recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability Index Europe (DJSI) for the fourth consecutive year.
10.01.2025Nilfisk präsentiert auf der Fachmesse für Intralogistik eine Vielzahl an Neuheiten...
17.01.2025ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.
14.01.2025ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.
14.01.2025Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally...
17.01.2025Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.
Sie sehen Artikel 19291 bis 19300 von insgesamt 19588